Janssen and Onyx Pharmaceuticals ally on combination cancer therapy research

Janssen has announced a new clinical trial and supply agreement with Onyx Pharmaceuticals, a subsidiary of Amgen.

The partnership will aim to evaluate the efficacy and safety of Janssen's first-in-class CD38-directed immunotherapy Darzalex in combination with Amgen's proteasome inhibitor therapy Kyprolis and dexamethasone.

This agreement covers all potential opportunities for combining these drugs for the treatment of patients with cancer, with the first study to be a phase III trial assessing the progression-free survival benefits of this regimen for multiple myeloma patients.

Dosing for this study is expected to commence in 2017, with the trial to be sponsored by Amgen. Meanwhile, a second trial will evaluate the safety and pharmacokinetics of this combination, in addition to a second regimen of Darzalex in combination with Kyprolis, lenalidomide and dexamethasone.

These studies will build on the promising results generated by the prior phase III POLLUX and CASTOR clinical studies.

Dr Peter Lebowitz, global oncology head of Janssen Research and Development, said: "This collaboration reflects our shared vision to better meet the needs of patients with multiple myeloma who are still in need of new therapeutic options."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.